Galápagos NV, which performs discovery research for itself and for other companies using a functional genomics platform, has acquired Argenta Discovery Ltd, a privately-held contract research organization, for €16.5 million in cash.
A private equity group with offices in London and Guernsey is providing £5 million over three years to a UK company pursuing a new concept in biologic development.
Ipsen SA of France is combining its holdings of potential haemophilia drugs with those of Inspiration Biopharmaceuticals Inc of California, US to create a franchise that Ipsen hopes will exceed $1 billion by 2020.
The privately-held Danish diagnostics company, Dako Denmark A/S, has signed a deal with AstraZeneca to develop companion diagnostic tests for a number of AstraZeneca’s oncology projects. Financial details were not disclosed.
BioMedPartners of Switzerland said that it has closed its second healthcare venture capital fund, BioMedInvest II, at CHF 106 million (€71.7 million). The new fund will invest in private, early to mid-stage healthcare companies in Europe.
Bavarian Nordic A/S, the Danish vaccine developer, has fixed the terms for its DKK 318.1 million (€42.7 million) rights issue.
Galápagos NV has entered into an alliance with Roche to develop potential therapies for chronic obstructive pulmonary disease (COPD). Galápagos has received €6 million upfront and said potential milestone payments could exceed €400 million.
Proximagen Neuroscience Plc, a university spin-out that raised £50 million in an offer of its shares in 2009, is making an agreed, all-cash offer for Minster Pharmaceuticals Plc. Both companies are developing CNS drug candidates.
The Danish antibody developer, Affitech A/S, has negotiated a bridging loan of DKK 9.33 million (€1.25 million) to cover its needs while it negotiates a larger financing during the first quarter. The loan has been extended by three existing investors.
Pharming Group NV has raised €7.5 million in convertible debt that will help finance its activities while its lead product for hereditary angioedema, Rhucin, is being reviewed by the European Medicines Agency.